Organisation paid for research Program year 2024 Source: CMS Open Payments

BTC Network LLC

Neither a doctor nor a teaching hospital

Research payments

$271,614

54 payments

Through program year 2024, BTC Network LLC is reported as receiving $271,614 in research payments, across 54 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $1,250 1
2023 Research $8,053 3
2022 Research $25,779 11
2021 Research $34,485 14
2020 Research $196,862 20
2019 Research $5,184 5

Breakdown

Who paid Research payments · program years 2019–2024
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $95,398 3 payments
  2. Guerbet LLC $82,638 6 payments
  3. H. Lundbeck A S $37,789 17 payments
  4. Myovant Sciences Inc. $21,874 12 payments
  5. AbbVie, Inc. $20,557 7 payments
  6. Sumitomo Pharma America, Inc. $6,553 2 payments
  7. Supernus Pharmaceuticals, Inc. $4,009 3 payments
  8. Amneal Pharmaceuticals LLC $1,620 2 payments
  9. Shionogi Inc $1,175 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Randomized, Placebo-Controlled Trial to Evaluate the Longer-Term (Ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder $95,398 3 payments
  2. Picture $74,378 5 payments
  3. A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing An Acute Attack of Migraine $37,789 17 payments
  4. A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder $18,307 5 payments
  5. Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) $8,260 1 payment
  6. Spirit Extension: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $8,079 4 payments
  7. Spirit Extension An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $7,972 6 payments
  8. Spirit Extension: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $6,553 2 payments
  9. An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids $5,823 2 payments
  10. Evaluation of Spn-812 Er 200 and 400 MG Efficacy and Safety in Children With Adhd - A Double-Blind, Placebo-Controlled, Pivotal Trial $3,831 1 payment
What the money was spent on Research payments · program years 2019–2024
  1. Patient care $8,260 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record